Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cell carcinoma. The prognosis for patients with ccRCC has improved over recent years with the use of combination therapies with an anti-programmed death-1 (PD-1) backbone. This has enhanced the quality of life and life expectancy of patients with this disease. Unfortunately, not all patients benefit; eventually, most patients will develop resistance to therapy and progress. Recent molecular, biochemical, and immunological research has extensively researched anti-angiogenic and immune-based treatment resistance mechanisms. This analysis offers an overview of the principles underpinning the resistance pathways related to immune checkpoint inhibitors (ICIs). Additionally, novel approaches to overcome resistance that may be considered for the trial context are discussed.

Keywords

Renal cell carcinoma / immunotherapy / treatment resistance / tumor microenvironment / intrinsic factors

References

[1] Siegel RL,Jemal A.Cancer statistics, 2019.CA Cancer J Clin2019;69:7-34

[2] Sung H,Siegel RL.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] Ferlay J,Soerjomataram I.Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.Eur J Cancer2018;103:356-87

[4] Capitanio U,Bex A.Epidemiology of renal cell carcinoma.Eur Urol2019;75:74-84 PMCID:PMC8397918

[5] Dabestani S,Lindblad P,Ljungberg B.Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.World J Urol2016;34:1081-6

[6] Rosenblatt J.Immunotherapy for renal cell carcinoma.Hematol Oncol Clin North Am2011;25:793-812

[7] Choueiri TK.Systemic therapy for metastatic renal-cell carcinoma.N Engl J Med2017;376:354-66

[8] Clark JI,Kaufman HL.Impact of sequencing targeted therapies with high-dose interleukin-2 immunotherapy: an analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational IL-2 clinical trial: PROCLAIM^SM.Clin Genitourin Cancer2017;15:31-41.e4 PMCID:PMC6875755

[9] Motzer RJ,Eisen T.Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.J Clin Oncol2013;31:3791-9 PMCID:PMC5569677

[10] Motzer RJ,Atkins MB.Final overall survival and molecular analysis in immotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs. sunitinib in patients with previously untreated metastatic renal cell carcinoma.JAMA Oncol2022;8:275-80 PMCID:PMC8855230

[11] Navani V.Treatment selection in first-line metastatic renal cell carcinoma-the contemporary treatment paradigm in the age of combination therapy: a review.JAMA Oncol2022;8:292-9

[12] Kluger HM,Ascierto ML.Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.J Immunother Cancer2020;8:e000398 PMCID:PMC7174063

[13] Schwartz LH,de Vries E.RECIST 1.1-update and clarification: from the recist committee.Eur J Cancer2016;62:132-7 PMCID:PMC5737828

[14] Navani V,Mandaliya H.Melanoma: an immunotherapy journey from bench to bedside.Cancer Treat Res2022;183:49-89

[15] Conforti F,Bagnardi V.Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis.Lancet Oncol2018;19:737-46

[16] Polanczyk MJ,Vandenbark AA.Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway.J Neurosci Res2006;84:370-8

[17] Polanczyk MJ,Vandenbark AA.Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1).Int Immunol2007;19:337-43

[18] Motzer RJ,Escudier B.Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).J Clin Oncol2020;38:617-617

[19] Farag KI,Norian LA.Re-evaluating the effects of obesity on cancer immunotherapy outcomes in renal cancer: what do we really know?.Front Immunol2021;12:668494 PMCID:PMC8374888

[20] Sanchez A,Kuo F.Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.Lancet Oncol2020;21:283-93

[21] Labadie BW,Bao R.BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.J Transl Med2019;17:386 PMCID:PMC6878694

[22] Bergerot PG,Philip EJ.Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma.Kidney Cancer3(1):2019;63-70

[23] De Giorgi U,Giannarelli D.Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab.Clin Cancer Res2019;25:3839-46

[24] Boi SK,Gibson JT.Obesity diminishes response to PD-1-based immunotherapies in renal cancer.J Immunother Cancer2020;8:e000725 PMCID:PMC7757487

[25] Chowell D,Grigg CM.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Science2018;359:582-7 PMCID:PMC6057471

[26] Chowell D,Pierini F.Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.Nat Med2019;25:1715-20 PMCID:PMC7938381

[27] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[28] Dizman N,Bergerot PG.Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma.Cancer Med2021;10:79-86 PMCID:PMC7826461

[29] Elkrief A,Kroemer G,Routy B.The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?.Ann Oncol2019;30:1572-9

[30] Lalani AA,Braun DA.Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma.Eur Urol Oncol2020;3:372-81 PMCID:PMC9163676

[31] Derosa L,Spaziano M.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol2018;29:1437-44 PMCID:PMC6354674

[32] Tinsley N,Tan G.Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer.Oncologist2020;25:55-63 PMCID:PMC6964118

[33] Arbour KC,Long N.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.J Clin Oncol2018;36:2872-8

[34] Santini FC,Plodkowski AJ.Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC.Cancer Immunol Res2018;6:1093-9 PMCID:PMC6125223

[35] Horvat TZ,Dang TO.Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center.J Clin Oncol2015;33:3193-8 PMCID:PMC5087335

[36] Weber JS,Wolchok JD.Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.J Clin Oncol2017;35:785-92

[37] Watson AS,Stukalin I.Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy.JAMA Netw Open2022;5:e2245596 PMCID:PMC9856439

[38] Kalbasi A.Tumour-intrinsic resistance to immune checkpoint blockade.Nat Rev Immunol2020;20:25-39 PMCID:PMC8499690

[39] Restifo NP,Kawakami Y.Identification of human cancers deficient in antigen processing.J Exp Med1993;177:265-72 PMCID:PMC1950463

[40] Platanias LC.Mechanisms of type-I- and type-II-interferon-mediated signalling.Nat Rev Immunol2005;5:375-86

[41] Zaretsky JM,Shin DS.Mutations associated with acquired resistance to PD-1 blockade in melanoma.N Engl J Med2016;375:819-29 PMCID:PMC5007206

[42] Boni A,Dang P.Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer Res2010;70:5213-9

[43] Ricketts CJ,Fan H.Cancer genome atlas research networkThe cancer genome atlas comprehensive molecular characterization of renal cell carcinoma.Cell Rep2018;23:313-326.e5 PMCID:PMC6075733

[44] Peng W,Liu C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy.Cancer Discov2016;6:202-16 PMCID:PMC4744499

[45] Spranger S,Gajewski TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.Nature2015;523:231-5

[46] Sweis RF,Bao R.Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer.Cancer Immunol Res2016;4:563-8 PMCID:PMC4943758

[47] Seiwert TY,Keck MK.Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.Clin Cancer Res2015;21:632-41 PMCID:PMC4305034

[48] Jiménez-Sánchez A,Pourpe S.Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient.Cell2017;170:927-938.e20 PMCID:PMC5589211

[49] Sarvaria A,Saudemont A.B cell regulation in cancer and anti-tumor immunity.Cell Mol Immunol2017;14:662-74 PMCID:PMC5549607

[50] Rosser EC.Regulatory B cells: origin, phenotype, and function.Immunity2015;42:607-12

[51] Mier JW.The tumor microenvironment in renal cell cancer.Curr Opin Oncol2019;31:194-9 PMCID:PMC6467495

[52] Chanmee T,Konno K.Tumor-associated macrophages as major players in the tumor microenvironment.Cancers2014;6:1670-90 PMCID:PMC4190561

[53] Komohara Y,Ohnishi K.Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma.Cancer Sci2011;102:1424-31

[54] Santoni M,Amantini C.Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.Cancer Immunol Immunother2013;62:1757-68

[55] Voss MH,Hellmann MD.Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).J Clin Oncol2018;36:4518-4518

[56] Vano Y,Dalban C.NIVOREN GETUG-AFU 26 translational study: association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).J Clin Oncol2020;38:618-618

[57] Fridman WH,Sautès-Fridman C.The immune contexture in human tumours: impact on clinical outcome.Nat Rev Cancer2012;12:298-306

[58] Becht E,Lacroix L.Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.Genome Biol2016;17:218 PMCID:PMC5073889

[59] Choueiri TK,Powles T.METEOR investigatorsCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Lancet Oncol2016;17:917-27

[60] Zhang S,Long J.Immune infiltration in renal cell carcinoma.Cancer Sci2019;110:1564-72 PMCID:PMC6501001

[61] Helmink BA,Gao J.B cells and tertiary lymphoid structures promote immunotherapy response.Nature2020;577:549-55 PMCID:PMC8762581

[62] Finkin S,Stein I.Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.Nat Immunol2015;16:1235-44 PMCID:PMC4653079

[63] Stubbs M,Griffiths JR.Causes and consequences of tumour acidity and implications for treatment.Mol Med Today2000;6:15-9

[64] Sormendi S.Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment.Front Immunol2018;9:40 PMCID:PMC5796897

[65] Khan KA.Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.Nat Rev Clin Oncol2018;15:310-24

[66] Garcia-Lora A,Garrido F.MHC class I antigens, immune surveillance, and tumor immune escape.J Cell Physiol2003;195:346-55

[67] Yu W.Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature.Medicine2018;97:e11614 PMCID:PMC6078683

[68] Zhang J,Xu X,Mi J.The influence of microenvironment on tumor immunotherapy.FEBS J2019;286:4160-75 PMCID:PMC6899673

[69] Romero-Garcia S,Prado-Garcia H.Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance.Front Immunol2016;7:52 PMCID:PMC4754406

[70] Beuselinck B,Becht E.Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.Clin Cancer Res2015;21:1329-39

[71] Epaillard N,Elaidi R.BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.Bull Cancer2020;107:eS22-7

[72] Meylan M,Elaidi R.1451MO In-situ immune markers predict nivolumab (N)+/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial.Annals of Oncolog2022;33:S1207

[73] McDermott DF,Atkins MB.Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Nat Med2018;24:749-57 PMCID:PMC6721896

[74] Rini BI,Atkins MB.IMmotion151 study groupAtezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.Lancet2019;393:2404-15

[75] Motzer RJ,Hamidi H.Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade.Cancer Cell2020;38:803-817.e4 PMCID:PMC8436590

[76] Hamieh L,Le VH.The Efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy.Clin Genitourin Cancer2020;18:252-257.e2 PMCID:PMC7415534

[77] Santoni M,Massari F.Nivolumab VERSUS cabozantinib as second-line therapy in patients with advanced renal cell carcinoma: a real-world comparison.Clin Genitourin Cancer2022;20:285-95

[78] Pal SK,Suárez C.Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study.J Clin Oncol2021;39:3725-36 PMCID:PMC8601305

[79] Cannarile MA,Jacob W,Ries CH.Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.J Immunother Cancer2017;5:53 PMCID:PMC5514481

[80] Seeber A,Fritz J.High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.Cancer Sci2018;109:1583-91 PMCID:PMC5980224

[81] Mitchell TC,Smith DC.Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase i results from a multicenter, open-label phase i/ii trial (ECHO-202/KEYNOTE-037).J Clin Oncol2018;36:3223-30 PMCID:PMC6225502

[82] Long GV,Hamid O.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.Lancet Oncol2019;20:1083-97

[83] Corrales L,McWhirter SM.Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity.Cell Rep2015;11:1018-30 PMCID:PMC4440852

[84] Poeck H,Maihoefer C.5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.Nat Med2008;14:1256-63

[85] Choueiri TK,Papadopoulos KP.Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.Nat Med2021;27:802-5 PMCID:PMC9128828

[86] Choueiri TK,Merchan J.Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.Lancet Oncol2023;24:553-62

[87] Rini BI,Figlin RA.Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.J Clin Oncol2019;37:558-558

[88] Grimm EA,Zhang HZ.Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.J Exp Med1982;155:1823-41 PMCID:PMC2186695

[89] Gillis S.Interleukin 2: biology and biochemistry.J Clin Immunol1983;3:1-13

[90] Chatzkel JA,Ludlow S.Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.J Clin Oncol2019;37:7_suppl, 657-657

[91] Diab A,Cho DC.NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.J Clin Oncol2018;36:3006-3006

[92] Dizman N,Bergerot P.Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.Nat Med2022;28:704-12 PMCID:PMC9018425

[93] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103 PMCID:PMC5827966

[94] Matson V,Bao R.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.Science2018;359:104-8 PMCID:PMC6707353

[95] Cortellini A,Palumbo P.Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.Sci Rep2020;10:1456 PMCID:PMC6989679

[96] Jerby-Arnon L,Cuoco MS.A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade.Cell2018;175:984-997.e24 PMCID:PMC6410377

[97] Deng J,Jenkins RW.CDK4/6 Inhibition augments antitumor immunity by enhancing T-cell activation.Cancer Discov2018;8:216-33 PMCID:PMC5809273

[98] Sade-Feldman M,Chen JH.Resistance to checkpoint blockade therapy through inactivation of antigen presentation.Nat Commun2017;8:1136 PMCID:PMC5656607

[99] Wang X,Chen X.Drug resistance and combating drug resistance in cancer.Cancer Drug Resist2019;2:141-60 PMCID:PMC8315569